Original Research
Published on 01 Oct 2025
Cost-effectiveness of HLX01 (Hanlikang®) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model analysis
in Drugs Outcomes Research and Policies
- 378 views